A Phase 3 interventional study of MRTX849 and Cetuximab in Advanced Colorectal Cancer and Metastatic Colorectal Cancer, sponsored by Mirati Therapeutics Inc.. Active, not recruiting at 419 sites in 32 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Mirati Therapeutics Inc. (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb — 4 open to participants now, 9 under way, 3 of them phase 3. Colorectal Neoplasms · Bristol-Myers Squibb.
Among the 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb, this one is the 5th largest by enrollment of the 27 interventional ones that give a count, is the only one that started in 2021, is one of 3 in phase 3, and was the 18th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →4 of the 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 22 more countries
Ages 18+
Bristol-Myers Squibb · Sites in United States, Canada, Spain
Ages 18+
Bristol-Myers Squibb · Sites in United States, Australia, Canada
Ages 18+
Bristol-Myers Squibb · Sites in United States, Canada
Ages 18+
By country, each count listing its studies:
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 17 · Phase 3 5
First in 2002; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 461 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 171 across the 27 interventional studies, 124 across the 1 observational. Of the 20 that completed or were terminated, 9 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Mirati Therapeutics Inc., one of the names counted as Bristol-Myers Squibb. Under that name alone:
Mirati Therapeutics Inc. is the lead sponsor of 51 studies on the registry; 3 are open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 4 (20%) have results posted.
2 of the studies in Colorectal Neoplasms by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06544655Bristol-Myers SquibbA Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors | 2027-10-14 |
| NCT06764771Bristol-Myers SquibbA Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors | 2027-10-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: MRTX849 · Biological: Cetuximab
Drug: mFOLFOX6 Regimen · Drug: FOLFIRI Regimen
Overall Survival (OS)
Defined as time from date of randomization to date of death due to any cause.
Time frame: 30 months
Progression-free Survival (PFS)
Defined as time from randomization until disease progression or death from any cause, whichever occurs first.
Time frame: 30 months
Adverse Events
Defined as number of patients with treatment emergent AEs.
Time frame: 30 months
Objective Response Rate (ORR)
Defined as the percent of patients documented to have a confirmed CR or PR.
Time frame: 30 months
Duration of Response (DOR)
Defined as the time from date of the first documentation of objective tumor response (CR or PR) to the first documentation of either Progression of Disease (PD) or death due to any cause, whichever occurs first.
Time frame: 30 months
Patient Reported Outcomes (PROs)
To be assessed by European Quality of Life Questionnaire for Cancer Patients (QLQ-C30).
Time frame: 30 months
Quality of Life Assessment
To be assessed by European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L).
Time frame: 30 months
Showing the first 100 of 419 sites across 32 countries. Choose a country and city above to see the rest.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Ran from Jun 2021 to primary completion in Jan 2026, 54 months.
Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's 54 months is above that.
Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.
Completion moved once since we started tracking on Sep 25, 2026: Jul 2026 → Oct 2026, on Sep 28, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adagrasib